Undiscovered Gems With Potential To Explore In November 2024

As global markets react to the recent U.S. election results, small-cap stocks have seen a notable surge, with the Russell 2000 Index leading gains despite not reaching record highs. This environment of potential economic growth and regulatory changes highlights the importance of identifying stocks that are well-positioned to capitalize on these shifts, offering intriguing opportunities for investors seeking undiscovered gems in November 2024.

Top 10 Undiscovered Gems With Strong Fundamentals

Name

Debt To Equity

Revenue Growth

Earnings Growth

Health Rating

Marítima de Inversiones

NA

86.64%

24.51%

★★★★★★

Impellam Group

31.12%

-5.43%

-6.86%

★★★★★★

Ovostar Union

0.01%

10.19%

49.85%

★★★★★★

Linc

NA

12.52%

16.39%

★★★★★★

Tianyun International Holdings

10.09%

-5.59%

-9.92%

★★★★★★

HOMAG Group

NA

-31.14%

23.43%

★★★★★☆

Billion Industrial Holdings

3.63%

18.00%

-11.38%

★★★★★☆

Wilson

64.79%

30.09%

68.29%

★★★★☆☆

A2B Australia

15.83%

-7.78%

25.44%

★★★★☆☆

Inversiones Doalca SOCIMI

16.56%

6.15%

10.19%

★★★★☆☆

Click here to see the full list of 4673 stocks from our Undiscovered Gems With Strong Fundamentals screener.

Let's uncover some gems from our specialized screener.

Aurisco PharmaceuticalLtd

Simply Wall St Value Rating: ★★★★★☆

Overview: Aurisco Pharmaceutical Co., Ltd. is involved in the research, manufacturing, and marketing of pharmaceutical intermediates, specialty active pharmaceutical ingredients (APIs), and formulations for the global pharmaceutical market, with a market cap of CN¥9.26 billion.

Operations: Aurisco generates revenue primarily from pharmaceutical intermediates, specialty APIs, and formulations. The company's financials reveal a focus on optimizing production costs to enhance profitability. Notably, the net profit margin demonstrates significant variation across reporting periods.

Aurisco Pharma, a small player in the pharmaceutical sector, is showing promising signs with its earnings growth of 32.5% last year, outpacing the industry average. The company’s price-to-earnings ratio stands at 27.2x, below the CN market average of 36.3x, indicating potential value for investors. Recent financials reveal revenue for the first nine months reached CNY 1.09 billion (approx US$148 million), up from CNY 922 million (approx US$125 million) last year, while net income increased to CNY 284 million (approx US$39 million). Despite a debt-to-equity rise to 37%, it maintains more cash than total debt and high-quality non-cash earnings suggest robust financial health moving forward.